You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

MET exon14 deletion

Showing 1 - 25 of 1,753
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC, BRAF V600 Mutation, MET Exon 14 Mutation Trial in Guangzhou (Dabrafenib + Trametinib, Capmatinib)

Not yet recruiting
  • NSCLC
  • +2 more
  • Guangzhou, Guangdong, China
    Cancer Center of Sun-Yat Sen University
Sep 19, 2023

NSCLC Trial in Guangzhou (PLB1001)

Active, not recruiting
  • Non-small Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Guangdong Provincial People's Hospital
Aug 15, 2023

Metastatic NSCLC MET Exon 14 Skipping Mutation and Brain

Completed
  • Metastatic Non-Small Cell Lung Cancer
  • East Hanover, New Jersey
    18 Novartis Investigative Sites in the US
Dec 29, 2022

Gastric Cancer, Gastroesophageal-junction Cancer Trial in Gyeonggi-do (Tepotinib plus paclitaxel)

Recruiting
  • Gastric Cancer
  • Gastroesophageal-junction Cancer
  • Tepotinib plus paclitaxel
  • Gyeonggi-do, Korea, Republic of
    Hallym University Medical Center
Jun 29, 2022

Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial (procedure, biological, drug)

Not yet recruiting
  • Recurrent Lung Non-Small Cell Carcinoma
  • Stage IV Lung Cancer AJCC v8
  • Biospecimen Collection
  • +5 more
  • (no location specified)
Sep 7, 2023

Malignant Non-small Cell Tumor of Lung Stage IV Trial in Boston (Capmatinib (INC280))

Completed
Has Results
  • Malignant Non-small Cell Neoplasm of Lung Stage IV
  • Capmatinib (INC280)
  • Boston, Massachusetts
    Massachusetts General Hospital
Mar 11, 2022

Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer Trial in San Francisco (Capmatinib, Trametinib)

Recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • Stage IV Lung Cancer
  • San Francisco, California
    University of California San Francisco
Aug 15, 2022

Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping

Recruiting
  • Non-small Cell Lung Cancer
    • Changsha, Hunan, China
      Yongchang Zhang
    Mar 1, 2022

    NSCLC, RET Driver Mutation, BRAF V600 Mutation Trial in Guanzhou (Toripalimab, Nab paclitaxel, Pemetrexed)

    Recruiting
    • Non-Small Cell Lung Cancer
    • +5 more
    • Toripalimab
    • +3 more
    • Guanzhou, Guangdong, China
      Guangdong Lung Cancer Institute, Guangdong Provincial People's H
    Apr 4, 2023

    Non-Small Cell Lung Carcinoma Trial (Capmatinib 150 mg, Capmatinib 200 mg)

    Recruiting
    • Non-Small Cell Lung Carcinoma
    • Capmatinib 150 mg
    • Capmatinib 200 mg
    • Guwahati, Assam, India
    • +7 more
    Dec 19, 2022

    Advanced Cancer, Non Small Cell Lung Cancer Trial (Tepotinib, Pembrolizumab)

    Not yet recruiting
    • Advanced Cancer
    • Non Small Cell Lung Cancer
    • (no location specified)
    Mar 28, 2023

    NSCLC (NSCLC) Trial in China (Capmatinib)

    Recruiting
    • Non-Small Cell Lung Cancer (NSCLC)
    • Xiamen, Fujian, China
    • +18 more
    Jan 27, 2023

    Advanced NSCLC Trial (CT053PTSA)

    Not yet recruiting
    • Advanced NSCLC
    • (no location specified)
    Jul 29, 2021

    NSCLC Trial in United States (capmatinib)

    Recruiting
    • Non-small Cell Lung Cancer
    • La Jolla, California
    • +7 more
    Oct 5, 2022

    Carcinoma, Non-Small Cell Lung, NSCLC, Non-Small-Cell Lung Carcinoma Trial (Capmatinib)

    Available
    • Carcinoma, Non-Small Cell Lung
    • +3 more
    • (no location specified)
    Aug 31, 2021

    NSCLC, Solid Tumor Trial in Boston (Merestinib)

    Active, not recruiting
    • Carcinoma, Non-Small-Cell Lung
    • Solid Tumor
    • Boston, Massachusetts
    • +1 more
    Jan 26, 2022

    NSCLC Metastatic Trial in Shanghai (Savolitinib)

    Recruiting
    • Non-small Cell Lung Cancer Metastatic
    • Shanghai, Shanghai, China
      Shanghai Chest Hospital
    Aug 30, 2021

    Tabrecta® (Capmatinib) in South Korea

    Not yet recruiting
    • Non-Small-Cell Lung Carcinoma
    • Capmatinib
    • (no location specified)
    Jan 19, 2023

    NSCLC Trial in Worldwide (INC280 (capmatinib))

    Active, not recruiting
    • Carcinoma, Non-Small-Cell Lung
    • INC280 (capmatinib)
    • Long Beach, California
    • +95 more
    Dec 29, 2022

    Solid Tumor, MET Exon 14 Skipping Mutation, MET Amplification Trial in Korea, Republic of (Tepotinib)

    Recruiting
    • Solid Tumor
    • +2 more
    • Hwasun, Chonnam, Korea, Republic of
    • +21 more
    Nov 30, 2020

    Advanced (Stage IIIB/IV) NSCLC (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification Trial in Worldwide

    Active, not recruiting
    • Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification
    • Duarte, California
    • +140 more
    Jun 7, 2022

    NSCLC Trial in Canton, Houston (FWD1509 MsOH)

    Recruiting
    • Carcinoma, Non-Small-Cell Lung
    • FWD1509 MsOH
    • Canton, Ohio
    • +1 more
    Jul 20, 2022

    Special Drug Use-results Surveillance of Tabrecta Tablets

    Recruiting
    • Non-small Cell Lung Cancer
    • Tabrecta tablets
    • Nagoya, Aichi, Japan
    • +44 more
    Aug 1, 2022

    Cystinosis, Cystinosis, Nephropathic, Spinal Muscular Atrophy Trial in Germany (molecular-based screening)

    Completed
    • Cystinosis
    • +2 more
    • molecular-based screening
    • Rosenheim, Bavaria, Germany
    • +3 more
    Aug 30, 2023

    Duchenne Muscular Dystrophy Trial in Worldwide (SRP-4045, SRP-4053, Placebo)

    Active, not recruiting
    • Duchenne Muscular Dystrophy
    • Phoenix, Arizona
    • +74 more
    Jan 17, 2023